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Clinical PerspectiveWhat Is New?The study identifies 12 genetic determinants of circulating glycine levels, 7 of which are novel and not previously known to be involved in the metabolism of this amino acid.Biological mechanisms for half of the loci associated with circulating glycine levels are not directly evident.What Are the Clinical Implications?Although findings from this study provide additional insight into the genetic architecture of glycine metabolism, they do not yield conclusive evidence for a causal relationship between circulating levels of this amino acid and coronary artery disease in humans.

Introduction {#jah34102-sec-0008}
============

Metabolites derived from gut microbiome and hepatic‐mediated metabolism of dietary choline and [l]{.smallcaps}‐carnitine, such as trimethylamine *N*‐oxide and betaine, have recently been shown to be proatherogenic in mice and novel biomarkers of coronary artery disease (CAD) risk in humans.[1](#jah34102-bib-0001){ref-type="ref"}, [2](#jah34102-bib-0002){ref-type="ref"}, [3](#jah34102-bib-0003){ref-type="ref"} In searching for genetic determinants of these metabolites, we identified sexually dimorphic associations between the carbamoyl‐phosphate synthase 1 (*CPS1*) locus and not only plasma trimethylamine *N*‐oxide and betaine levels, but also other intermediates in the metabolic pathway leading from choline to urea.[4](#jah34102-bib-0004){ref-type="ref"} We and others further noted that, of the various other biomarkers/metabolites that had previously been linked to *CPS1*,[5](#jah34102-bib-0005){ref-type="ref"}, [6](#jah34102-bib-0006){ref-type="ref"}, [7](#jah34102-bib-0007){ref-type="ref"}, [8](#jah34102-bib-0008){ref-type="ref"}, [9](#jah34102-bib-0009){ref-type="ref"}, [10](#jah34102-bib-0010){ref-type="ref"}, [11](#jah34102-bib-0011){ref-type="ref"}, [12](#jah34102-bib-0012){ref-type="ref"}, [13](#jah34102-bib-0013){ref-type="ref"}, [14](#jah34102-bib-0014){ref-type="ref"} the strongest effect size and most significant association was with circulating glycine levels in women.[4](#jah34102-bib-0004){ref-type="ref"}, [15](#jah34102-bib-0015){ref-type="ref"}, [16](#jah34102-bib-0016){ref-type="ref"}, [17](#jah34102-bib-0017){ref-type="ref"} Most important, the lead *CPS1* variant also exhibited a strikingly significant female‐specific association with decreased risk of CAD.[4](#jah34102-bib-0004){ref-type="ref"} However, the direction of the associations between *CPS1* and the various biomarkers and metabolites was opposite to what would be expected for a variant that decreased risk of CAD.

One explanation for the protective association of *CPS1* with CAD could be the strong genetic effect of this locus on increased circulating glycine levels.[4](#jah34102-bib-0004){ref-type="ref"} For example, previous in vitro and in vivo studies have shown that glycine reduces inflammation and oxidative stress in endothelial cells, activated macrophages, and other leukocytes.[18](#jah34102-bib-0018){ref-type="ref"}, [19](#jah34102-bib-0019){ref-type="ref"}, [20](#jah34102-bib-0020){ref-type="ref"}, [21](#jah34102-bib-0021){ref-type="ref"}, [22](#jah34102-bib-0022){ref-type="ref"} Furthermore, platelet aggregation of both human and rodent platelets can be prevented by glycine in a dose‐dependent manner through mechanisms involving the glycine receptor.[23](#jah34102-bib-0023){ref-type="ref"} Interestingly, the same glycine‐raising *CPS1* variant has been associated with reduced platelet counts.[24](#jah34102-bib-0024){ref-type="ref"} Alternatively, glycine has been reported to have antihypertensive effects in mice and humans.[25](#jah34102-bib-0025){ref-type="ref"} A recent epidemiological study also demonstrated an inverse relationship between plasma glycine levels and risk of an acute myocardial infarction.[26](#jah34102-bib-0026){ref-type="ref"} Taken together, these observations support the concept that glycine could have atheroprotective properties, but direct evidence for a causal relationship between this amino acid and risk of CAD is lacking.

In the present study, we used a meta‐analysis approach with genome‐wide association study (GWAS) data to identify additional genetics determinants of circulating glycine levels. The identified loci were then used to investigate the possible causal association between circulating glycine levels and risk of CAD and traditional risk factors. In total, 12 loci were identified for circulating glycine levels, 7 of which were novel and not previously known to be involved in glycine metabolism. However, various analytical approaches with glycine‐raising alleles at these loci did not provide conclusive evidence for a causal relationship between circulating glycine and risk of CAD in humans.

Methods {#jah34102-sec-0009}
=======

The statistical methods used in this study will be made available to other researchers for purposes of reproducing the results or replicating the analyses. The summary statistics of the meta‐analysis for circulating glycine levels will be made available through the NHGRI‐EBI Catalog of published GWASs (<https://www.ebi.ac.uk/gwas/downloads/summary-statistics/>).

Study Populations {#jah34102-sec-0010}
-----------------

The present analyses included 30 118 subjects of European ancestry from the GeneBank (GB),[4](#jah34102-bib-0004){ref-type="ref"} FINRISK 1997 and 2007 (FR97 and FR07),[27](#jah34102-bib-0027){ref-type="ref"} YFS (Cardiovascular Risk in Young Finns Study),[28](#jah34102-bib-0028){ref-type="ref"} NFBC1966 and NFBC1986 (Northern Finland Birth Cohort),[29](#jah34102-bib-0029){ref-type="ref"} and METSIM (Metabolic Syndrome in Men)[30](#jah34102-bib-0030){ref-type="ref"} studies. Details of subject recruitment and genotyping methodology for each cohort are provided in Data [S1](#jah34102-sup-0001){ref-type="supplementary-material"}. For each cohort, written informed consent was obtained from all participants before being enrolled, and the studies were approved by the institutional review boards of the participating institutions. The present analysis was approved by the institutional review board of USC Keck School of Medicine.

Measurement of Circulating Glycine Levels {#jah34102-sec-0011}
-----------------------------------------

Glycine levels were quantified using stable isotope dilution high‐performance liquid chromatography with online electrospray ionization tandem mass spectrometry in the GB study[4](#jah34102-bib-0004){ref-type="ref"} and by quantitative high‐throughput NMR in the FR97, FR07, YFS NFBC66, NFBC86, and METSIM cohorts.[31](#jah34102-bib-0031){ref-type="ref"}, [32](#jah34102-bib-0032){ref-type="ref"}

Data Harmonization and GWAS Analyses {#jah34102-sec-0012}
------------------------------------

Circulating glycine levels were first regressed on study‐specific covariates chosen by the investigators of each cohort. These included age and sex in GeneBank; age, sex, and time from last meal in FR97, FR07, YFS NFBC66, and NFBC86[31](#jah34102-bib-0031){ref-type="ref"}; and age, age,[2](#jah34102-bib-0002){ref-type="ref"} and body mass index in METSIM.[32](#jah34102-bib-0032){ref-type="ref"} Inverse rank‐based normal transformations were carried out on the residuals after adjustment for covariates and used as the outcome in GWAS analyses by linear regression in each study.

Meta‐Analysis for Circulating Glycine Levels {#jah34102-sec-0013}
--------------------------------------------

We performed a fixed‐effects meta‐analysis for circulating glycine levels with 7 487 927 SNPs that were imputed using 1000 Genomes Project data and that were common to all data sets. This analysis was carried out assuming an additive model and after controlling for population structure within each study, as implemented in GWAMA (Genome‐Wide Association Meta‐Analysis) software.[33](#jah34102-bib-0033){ref-type="ref"} In addition to a combined meta‐analysis with all subjects, we also carried out a sex‐stratified fixed‐effects meta‐analysis. The genome‐wide threshold for significant association was set at *P*=5.0×10^−8^. A locus was defined as novel if the lead single‐nucleotide polymorphism (SNP) was in weak or no linkage disequilibrium (*r* ^2^≤0.1) with variants at genome‐wide significant loci previously reported for circulating glycine levels. Manhattan and quantile‐quantile plots were constructed using the "qqman" package in R (R Foundation for Statistical Computing, Vienna, Austria).[34](#jah34102-bib-0034){ref-type="ref"} To examine whether all novel loci identified in our meta‐analysis were also significantly associated with other traits (phenome‐wide association studies), we used publicly available databases, such as PhenoScanner,[35](#jah34102-bib-0035){ref-type="ref"} the UCSC Genome Browser (<https://genome.ucsc.edu/>), and the GWAS Catalog (<https://www.ebi.ac.uk/gwas/home>). The significance threshold for phenome‐wide association studies analyses was set to *P*=5.0×10^−8^ with a linkage disequilibrium cut off of *r* ^2^≥0.8 for proxy SNPs.

Proportion of Phenotypic Variance Explained {#jah34102-sec-0014}
-------------------------------------------

The proportion of variation in glycine levels explained by the identified variants was estimated using SumHer software.[36](#jah34102-bib-0036){ref-type="ref"} SNP heritability was calculated using a weighted linkage disequilibrium adjusted kinships model with the 12 glycine‐associated SNPs. 1000 Genomes Project--based imputed genotypes in ≈4500 subjects of European ancestry from the GB cohort were used as a reference panel for linkage disequilibrium (*r* ^2^) for these estimates.

Analysis of Variants With Risk of CAD and Traditional Risk Factors {#jah34102-sec-0015}
------------------------------------------------------------------

Publicly available summary results from large‐scale GWAS in subjects of European ancestry[37](#jah34102-bib-0037){ref-type="ref"}, [38](#jah34102-bib-0038){ref-type="ref"}, [39](#jah34102-bib-0039){ref-type="ref"} were used to determine whether glycine‐associated variants were associated with risk of CAD and various lipid‐, metabolic‐, and blood‐pressure--related risk factors. Specifically, we tested associations using 3 analytical strategies with 4 genetic models that were based on various nested combinations of the 12 identified variants. Genetic model 1 included all 12 loci identified for glycine; model 2 was designed to specifically test only the 7 novel loci (*ACADM*,*PHGDH*,*COX18‐ADAMTS3*,*PSPH*,*TRIB1*,*PTPRD*, and *ABO*); and model 3 included only the 4 loci known to be related to glycine metabolism (*PSPH*,*PHGDH*,*GLDC*, and *GCSH*). Model 4 was the most restrictive and included only the 2 glycine‐associated loci that are known to be directly involved in the catabolism of glycine through the glycine cleavage system (*GLDC* and *GCSH*) and that did not exhibit pleiotropic effects with other traits or metabolites. In the first analytical approach, the average/overall association of CAD and its risk factors with glycine‐raising alleles in the 4 genetic models were evaluated by meta‐analysis, as implemented in the "meta" R package (<https://cran.r-project.org/web/packages/meta/index.html>). In the second approach, we generated genetic risk scores (GRS) with the identified variants for the same 4 genetic models to evaluate the cumulative joint effects of glycine‐raising alleles. Additive multi‐SNP GRS associations were estimated using the grs.summary function of the "gtx: Genetic ToolboX" R package (<https://cran.r-project.org/web/packages/gtx>). This approach approximates the regression of an intermediate trait or biomarker onto a GRS, which is based on the weighted sum of the single SNP coefficients derived from the association summary statistics.[40](#jah34102-bib-0040){ref-type="ref"} For the third strategy, we carried out weighted median and inverse variance weighted Mendelian randomization (MR) analyses with the 4 genetic models, as implemented in the "TwoSampleMR" R package.[41](#jah34102-bib-0041){ref-type="ref"} Because the weighted median MR method requires 3 or more variants, only the inverse variance weighted MR test was used for determining association of the 2 SNPs in model 4 with CAD and traditional risk factors.

Results {#jah34102-sec-0016}
=======

GWAS for Circulating Glycine Levels {#jah34102-sec-0017}
-----------------------------------

To identify novel loci for circulating glycine levels, we carried out a meta‐analysis of GWAS summary‐level data with 7 487 927 genotyped and imputed SNPs in 30 118 subjects of European ancestry. Table [1](#jah34102-tbl-0001){ref-type="table"} shows the characteristics of the study cohorts and data sets used for these analyses. A GWAS was carried out for circulating glycine levels in each cohort, followed by a fixed‐effects meta‐analysis. The genomic control factor (lambda, λ) in GB I (0.995), GB II (0.989), and the combination of the FR97, FR07, YFS NFBC66, and NFBC86 cohorts (1.039), and METSIM (1.014) were small or modest, thus decreasing the likelihood of identifying spurious associations attributed to population stratification (Figure [S1](#jah34102-sup-0001){ref-type="supplementary-material"}). To further account for this potential confounder, we also applied genomic control to each study before the meta‐analysis. In total, 4934 variants distributed across 12 loci were associated with circulating glycine levels at the genome‐wide significance threshold (*P*=5.0×10^−8^; Figure [1](#jah34102-fig-0001){ref-type="fig"}, Table [2](#jah34102-tbl-0002){ref-type="table"}, and Table [S1](#jah34102-sup-0002){ref-type="supplementary-material"}). Seven of these loci (*ACADM*,*PHGDH*,*COX18‐ADAMTS3*,*PSPH*,*TRIB1*,*PTPRD*, and *ABO*) were novel and identified as being associated with circulating glycine levels for the first time herein (Figure [1](#jah34102-fig-0001){ref-type="fig"}, Table [2](#jah34102-tbl-0002){ref-type="table"}, and Figure [S2](#jah34102-sup-0001){ref-type="supplementary-material"}). The other 5 loci (*CPS1*,*ALDH1L1*,*PPP1R3B‐LOC157273*,*GLDC*, and *GCSH*) have previously been reported for circulating glycine levels, but the association signals became more significant in our meta‐analysis because of increased sample size (Figure [1](#jah34102-fig-0001){ref-type="fig"}, Table [2](#jah34102-tbl-0002){ref-type="table"}, and Figure [S2](#jah34102-sup-0001){ref-type="supplementary-material"}). Overall, the 12 identified loci explained ≈15% of the variation in circulating glycine levels.

###### 

Description of Cohorts Used in Meta‐Analysis for Circulating Glycine Levels

  Cohort   No. of SNPs   N (Male/Female)    Metabolomics Platform
  -------- ------------- ------------------ -----------------------
  GB I     8 986 545     391 (195/196)      HPLC‐MS
  GB II    8 986 545     885 (602/283)      HILIC‐MS
  FR97     11 512 433    6631 (3198/3433)   NMR
  FR07     11 512 433    4124 (1860/2264)   NMR
  YFS      11 512 433    1947 (1052/895)    NMR
  NFBC66   11 512 433    4483 (2152/2331)   NMR
  NFBC86   11 512 433    3112 (1508/1604)   NMR
  METSIM   16 888 882    8545 (8545/0)      NMR

FR97 and FR07 indicates FINRISK; GB, GeneBank; HPLC‐MS, high‐performance liquid chromatography with mass spectrometry; METSIM, METabolic Syndrome In Men Study; NFBC, Northern Finland Birth Cohort; NMR, nuclear magnetic resonance; SNP, single‐nucleotide polymorphism; YFS, Cardiovascular Risk in Young Finns.

![Results of GWAS meta‐analysis for circulating glycine levels. The Manhattan plot shows 7 novel significantly associated loci for circulating glycine levels (red dots) identified through meta‐analyses of GWAS data from 30 118 subjects in the GeneBank, FR97, FR07, YFS,NFBC66, NFBC86, and METSIM cohorts. The 5 previously known loci are indicated by blue dots and all increased in significance in the meta‐analysis. Genome‐wide thresholds for significant (*P*=5.0×10^−8^) and suggestive (*P*=5.0×10^−6^) association are indicated by the horizontal red and dark blue lines, respectively. *P* values are truncated at −log10 (*P*)=40. FR97 and FR07 indicates FINRISK; GWAS, genome‐wide association study; METSIM, METabolic Syndrome In Men Study; NFBC, Northern Finland Birth Cohort; YFS, Cardiovascular Risk in Young Finns.](JAH3-8-e011922-g001){#jah34102-fig-0001}

###### 

Meta‐Analysis Identifies 12 Loci Significantly Associated With Circulating Glycine Levels

  Locus (Nearest Gene(s))[a](#jah34102-note-0004){ref-type="fn"}   Lead SNP      Position (bp)[b](#jah34102-note-0005){ref-type="fn"}   Effect/Other Allele[c](#jah34102-note-0006){ref-type="fn"}   EAF    β (SE)        *P* Value        Direction[d](#jah34102-note-0007){ref-type="fn"}
  ---------------------------------------------------------------- ------------- ------------------------------------------------------ ------------------------------------------------------------ ------ ------------- ---------------- --------------------------------------------------
  1p31.1 (*ACADM*)                                                 rs12126607    76 217 097                                             A/G                                                          0.27   0.06 (0.01)   1.1×10^−11^      +−++
  1p12 (*PHGDH*)                                                   rs478093      120 255 126                                            G/A                                                          0.67   0.06 (0.01)   3.5×10^−10^      ++++
  2q34 (*CPS1*)                                                    rs1047891     211 540 507                                            A/C                                                          0.34   0.43 (0.01)   \<1.0×10^−300^   ++++
  3q21.3 (*ALDH1L1*)                                               rs2364368     125 905 080                                            T/A                                                          0.40   0.09 (0.01)   2.2×10^−28^      ++++
  4q13.3 (*COX18‐ADAMTS3*)                                         rs143424675   73 749 419                                             T/C                                                          0.03   0.19 (0.03)   7.3×10^−13^      +−++
  7p11.2 (*PSPH*)                                                  rs6955423     56 099 352                                             A/G                                                          0.81   0.07 (0.01)   2.3×10^−11^      ++++
  8p23.1 (*PPP1R3B‐LOC157273*)                                     rs2126263     9 181 611                                              G/A                                                          0.15   0.16 (0.01)   5.8×10^−44^      ++++
  8q24.13 (*TRIB1*)                                                rs28601761    126 500 031                                            G/C                                                          0.41   0.06 (0.01)   1.6×10^−13^      +−++
  9p24.1 (*GLDC*)                                                  rs71503800    6 102 648                                              T/C                                                          0.05   0.46 (0.02)   8.5×10^−121^     −++
  9p24.1 (*PTPRD*)                                                 rs12003835    8 424 378                                              T/G                                                          0.03   0.15 (0.03)   8.2×10^−9^       −++
  9q34.2 (*ABO*)[e](#jah34102-note-0008){ref-type="fn"}            rs492488      136 144 960                                            G/A                                                          0.55   0.05 (0.01)   1.2×10^−8^       −+++
  16q23.2 (*GCSH*)                                                 rs11860711    81 132 493                                             C/T                                                          0.80   0.12 (0.01)   4.2×10^−31^      ++++

EAF indicates effect allele frequency; SNP, single‐nucleotide polymorphism.

Novel loci identified in this study are highlighted in gray.

SNP base pair (bp) positions are given according to NCBI build 37 of the reference human genome sequence (hg19).

Effect allele refers to allele that increases glycine levels.

Direction of betas in the 4 data sets used for meta‐analysis are in the following order: GB I, GB II, Combination of FR97‐FR07‐YFS‐NFBC66‐NFBC86, and METSIM.

N=27 006 for chromosome 9q34.2 locus.

Based on previous observations that the *CPS1* locus exhibited a pattern of sexually dimorphic associations with glycine, various other metabolites, and risk of CAD,[4](#jah34102-bib-0004){ref-type="ref"}, [17](#jah34102-bib-0017){ref-type="ref"} we also carried out meta‐analyses in men and women separately. Five and 9 regions were significantly associated with circulating glycine levels in females and males, respectively (Figures [S3](#jah34102-sup-0001){ref-type="supplementary-material"} and [S4](#jah34102-sup-0001){ref-type="supplementary-material"}), all of which were also observed in the combined GWAS analysis with all subjects (Figure [1](#jah34102-fig-0001){ref-type="fig"}). With the exception of the previously observed stronger association signal for glycine levels at the *CPS1* locus in women (β=0.572; *P*\<1.0×10^−300^) compared with men (β=0.322; *P*=5.9×10^−189^), the effect sizes at the remaining 11 loci were similar in males and females with no significant evidence for heterogeneity (Table [S2](#jah34102-sup-0002){ref-type="supplementary-material"} and Figure [S5](#jah34102-sup-0001){ref-type="supplementary-material"}). We next carried out a phenome‐wide association studies analysis based on publicly available data to determine whether any of the loci for glycine were associated with other traits. Six of the 12 loci (*ACADM*,*CPS1*,*ALDH1L1*,*PPP1R3B‐LOC157273*,*TRIB1*, and *ABO*) exhibited pleiotropic associations with blood cell counts or lipid levels, some of which were even more significant than the association signals for glycine (Table [S3](#jah34102-sup-0002){ref-type="supplementary-material"}). Two other loci (*PSPH* and *PHGDH*) had also been associated with serine and homocysteine levels, which are metabolites related to glycine metabolism (Table [S3](#jah34102-sup-0002){ref-type="supplementary-material"}). However, no genome‐wide significant associations have previously been reported for the 4 remaining loci (*COX18‐ADAMTS3*,*GLDC*,*PTPRD*, and *GCSH*).

Association of Loci for Circulating Glycine Levels With CAD and Traditional Risk Factors {#jah34102-sec-0018}
----------------------------------------------------------------------------------------

We next sought to evaluate association of loci for glycine levels with risk of CAD and traditional risk factors. Of the 12 regions identified, glycine‐raising alleles of the lead variants at the *CPS1*,*PSPH*,*TRIB1*, and *ABO* loci individually yielded directionally consistent associations with decreased risk of CAD at the Bonferroni‐corrected threshold of *P*=4.2×10^−3^ for testing 12 loci (0.05/12; Table [S4](#jah34102-sup-0002){ref-type="supplementary-material"}). We next tested 4 genetic models based on various nested combinations of the 12 glycine loci for association with risk of CAD using 3 analytical strategies (details provided in [Methods](#jah34102-sec-0009){ref-type="sec"}). Consistent with the individual SNP results, meta‐analysis or GRS‐based joint SNP effects analysis of glycine‐raising alleles in all 4 genetic models yielded modest, but significant, associations (odds ratios, ≈0.98) with decreased risk of CAD (Figure [2](#jah34102-fig-0002){ref-type="fig"}). By comparison, weighted median and inverse variance weighted MR tests yielded much weaker or no evidence for a protective association of glycine‐raising alleles with CAD, including the most restrictive model constructed with only variants at the 2 glycine cleavage system loci (Figure [2](#jah34102-fig-0002){ref-type="fig"}). We next evaluated whether loci for glycine were associated with blood pressure, lipid levels, and obesity‐related traits using the same analytical strategies. Glycine‐raising alleles at several loci (*CPS1*,*PPP1R3B‐LOC157273*,*TRIB1*, and *ABO*) individually exhibited highly significant associations with decreased blood pressure and lipid levels (Table [S5](#jah34102-sup-0002){ref-type="supplementary-material"}). The meta‐analysis and GRS‐based joint SNP effects analysis also provided evidence for similar associations with blood pressure and lipid levels, although these were only observed for the genetic models that included either all 12 glycine‐associated loci or the 7 novel loci. However, the 2 MR analyses provided no evidence that glycine‐raising alleles were causally associated with any of the selected traditional risk factors (Table [S5](#jah34102-sup-0002){ref-type="supplementary-material"}).

![Association of loci identified for circulating glycine levels with risk of CAD. Individual associations between glycine‐raising alleles at each locus and risk of CAD are shown by blue squares in the forest plots. Purple diamonds indicate combined associations based on meta‐analysis, joint SNP effects with a genetic risk score (GRS), and weighted median (WM) or inverse variance weighted (IVW) Mendelian randomization (MR) test. Model 1 included all 12 glycine‐associated loci (A), model 2 included the 7 novel loci for glycine in this study (B), model 3 included the 4 loci known to be involved in glycine metabolism (C), and model 4 was constructed with only the 2 loci directly involved in the catabolism of glycine through the glycine cleavage complex (D). CAS indicates coronary artery disease; OR, odds ratio; SNP, single‐nucleotide polymorphism.](JAH3-8-e011922-g002){#jah34102-fig-0002}

Discussion {#jah34102-sec-0019}
==========

In the present study, we used a meta‐analysis approach to identify 7 novel genomic regions associated with circulating glycine levels and strengthen the association signals at 5 previously known loci. Among all 12 loci, *CPS1* and *GLDC* were the most strongly associated with glycine levels, with variants at the remaining 10 loci having anywhere between ≈60% and 90% lower effect sizes. Furthermore, sex‐stratified analyses confirmed the strong effect of *CPS1* on glycine levels in women compared with men, but did not reveal sexually dimorphic associations with any of the remaining 11 loci. Follow‐up analyses with the identified loci also yielded evidence that glycine could be causally associated with risk of CAD, although the biological mechanism(s) through which this effect occurs remains to be determined.

Based on what is known about amino acid metabolism, plausible biological links could be inferred between several of the newly identified loci and glycine levels. For example, *PHGDH* and *PSPH* encode phosphoglycerate dehydrogenase and phosphoserine phosphatase, which catalyze the first and last reactions, respectively, in the 3‐step process leading to the synthesis of serine from 3‐phosphoglycerate.[42](#jah34102-bib-0042){ref-type="ref"} Although the *PHGDH* and *PSPH* loci have both been strongly associated with circulating serine or homocysteine levels,[8](#jah34102-bib-0008){ref-type="ref"}, [15](#jah34102-bib-0015){ref-type="ref"}, [16](#jah34102-bib-0016){ref-type="ref"}, [43](#jah34102-bib-0043){ref-type="ref"}, [44](#jah34102-bib-0044){ref-type="ref"}, [45](#jah34102-bib-0045){ref-type="ref"}, [46](#jah34102-bib-0046){ref-type="ref"}, [47](#jah34102-bib-0047){ref-type="ref"} they were not known to be associated with glycine levels before the results of our meta‐analysis. Interestingly, serine can serve as a substrate for the synthesis of glycine in a reversible reaction catalyzed by *SHMT*,[48](#jah34102-bib-0048){ref-type="ref"} and glycine levels have been reported to be lower in humans deficient for *PHGDH* or *PSPH*.[49](#jah34102-bib-0049){ref-type="ref"}, [50](#jah34102-bib-0050){ref-type="ref"}, [51](#jah34102-bib-0051){ref-type="ref"}, [52](#jah34102-bib-0052){ref-type="ref"} With respect to our results, the lead variant at *PHDGH* has yielded several highly significant (*P* values ranging from ≈1.0×10^−10^ to 1.0×10^−34^) *cis* expression quantitative trait loci where the glycine‐raising allele of rs478093 (G) increases *PHGDH* mRNA levels.[35](#jah34102-bib-0035){ref-type="ref"} This would presumably lead to increased production of serine and, by extension, glycine, thus providing a directionally consistent molecular mechanism for the observed association of the *PHGDH* locus with circulating glycine levels. However, even when taking into account previously identified associations at loci harboring enzymes involved in either glycine catabolism (*GLDC*,*GCSH*)[53](#jah34102-bib-0053){ref-type="ref"}, [54](#jah34102-bib-0054){ref-type="ref"} or downstream detoxification through the urea cycle (*CPS1*),[55](#jah34102-bib-0055){ref-type="ref"}, [56](#jah34102-bib-0056){ref-type="ref"} biological mechanisms for half of the loci associated with circulating glycine levels are not directly evident.

A primary goal of our study was to test whether glycine is a causal and protective biomarker of CAD risk. To address this question, we used the results of large GWAS meta‐analyses to determine whether loci identified for glycine levels were associated with CAD and traditional risk factors. Glycine‐raising alleles at 3 of the 7 novel loci (*PSPH*,*TRIB1*, and *ABO*) were individually associated with decreased risk of CAD at the Bonferroni‐corrected significance threshold (*P*=4.2×10^−3^), of which *TRIB1* and *ABO* had been identified as CAD susceptibility loci in previous GWASs.[37](#jah34102-bib-0037){ref-type="ref"}, [57](#jah34102-bib-0057){ref-type="ref"}, [58](#jah34102-bib-0058){ref-type="ref"} Rather than glycine levels, it is likely that association of *TRIB1* and *ABO* with CAD is attributed to their stronger effect sizes on lipid levels and hematological parameters[12](#jah34102-bib-0012){ref-type="ref"}, [59](#jah34102-bib-0059){ref-type="ref"}, [60](#jah34102-bib-0060){ref-type="ref"} and, in the case of *ABO*, numerous other CAD‐relevant traits.[35](#jah34102-bib-0035){ref-type="ref"} When all 12 loci or only the 7 novel loci were considered in combination, the meta‐analyses and joint SNP effects analyses also revealed association of glycine‐raising alleles with decreased risk of CAD. Because several of the loci included in these analyses (*CPS1*,*PSPH*,*PPP1R3B‐LOC157273*,*TRIB1*, and *ABO*) exhibited associations with other CAD‐related traits, either individually or in various combinations, it was not possible based on these results alone to conclude that glycine is the causal biomarker driving the association of these loci with CAD. Therefore, we assessed causality more directly with 2 different MR tests, which provided little to no evidence that glycine‐raising alleles were associated with risk of CAD or lipid levels, blood pressure, and obesity‐related traits. In this regard, the results of MR tests with the most restrictive genetic model that included only the 2 loci directly involved in glycine degradation (*GLDC* and *GCSH*) are particularly relevant. For example, no CAD‐related traits, aside from glycine levels, are known to be associated with the *GLDC* and *GCSH* loci, thus satisfying the lack of pleiotropy as 1 of the major assumptions in MR analysis. Moreover, the glycine‐raising alleles of rs71503800 at the *GLDC* locus and rs1047891 at the *CPS1* locus have nearly equivalent effect sizes on circulating glycine levels. However, none of the analyses with rs71503800 at the *GLDC* locus yielded evidence for association of this variant with risk of CAD or traditional risk factors. Taken together, we conclude that evidence for a causal relationship between circulating glycine and risk of CAD is relatively weak and requires additional studies.

Whereas the present results have revealed novel genetic determinants of circulating glycine levels, our study should also be taken in the context of certain limitations. First, depending on the cohort, metabolomic analysis was carried out using different platforms and glycine was measured in either serum or plasma, some of which were not fasting samples. Although this may have led to identifying fewer significant associations for circulating glycine levels, our relatively large sample size in the meta‐analysis still provided sufficient power to detect robust associations at several previously known loci and 7 novel genomic regions. Second, the sex‐stratified analyses had approximately half the number of females than males, which likely decreased power to identify loci for circulating glycine levels that were either specific to, or more strongly associated in, 1 sex or the other. Third, all study subjects in our study were of European ancestry, and it is possible that the genetic association results for either circulating plasma glycine levels may not be generalizable to other populations. Last, our evaluation of the causal relationship between glycine and risk of CAD or traditional risk factors may have resulted in biased estimates because of pleiotropic effects, especially in models that included all 12 loci or the 7 newly identified SNPs, or because of weak instruments in nested models that included only the 4 or 2 loci directly involved in glycine metabolism.

In summary, the results of our study provide additional insight into the genetic architecture of glycine metabolism, but a more‐complete understanding of the mechanisms through which some of these loci influence circulating levels remains to be determined. Despite these genetic findings, we did not obtain conclusive evidence for a causal relationship between glycine and risk of CAD, raising the possibility that another unknown metabolite or biological pathway is driving the protective association of glycine‐raising alleles at the *CPS1* locus with risk of CAD.
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**Data S1.** Detailed description of cohorts.

**Figure S1.** Quantile‐quantile (Q‐Q) plot of GWAS meta‐analysis results for circulating glycine levels in 30 118 subjects. The observed vs the expected *P* values from the meta‐analyses for glycine levels are shown in the Q‐Q plot. These analyses yielded a genomic inflation factor (λ) of 1.035, indicating that the GWAS meta‐analyses were not confounded by underlying population stratification.

**Figure S2.** Twelve loci identified for circulating glycine associated levels. Regional plots for the *ACADM*,*PHGDH*,*CPS1*,*ALDH1L1*,*COX18‐ADAMTS3*,*PSPH*,*PPP1R3B‐LOC157273*,*TRIB1*,*GLDC*,*PTPRD*,*ABO*, and *GCSH* loci are shown in (A through L). Each region is centered on the lead SNP (purple diamond) and the genes in the interval are indicated in the bottom panel. The degree of linkage disequilibrium (LD) between the lead SNP and other variants is shown as *r* ^2^ values according to the color‐coded legend in the box.

**Figure S3.** Results of GWAS meta‐analysis for circulating glycine levels in women. A, The Manhattan plot shows 5 previously identified loci significantly associated with circulating glycine levels (blue dots) in a stratified GWAS analysis with 10 886 women. Red dots indicate association signals for the 7 novel identified in our meta‐analysis with all 30 118 subjects, all of which were only suggestively associated in women. Genome‐wide thresholds for significant (*P*=5.0×10^−8^) and suggestive (*P*=5.0×10^−6^) association are indicated by the horizontal red and dark blue lines, respectively. *P* values are truncated at −log10 (*P*)=40. B, The Q‐Q plot shows the observed vs the expected *P* values from the meta‐analyses for glycine levels in women. These analyses yielded a genomic inflation factor (λ) of 1.002, indicating that the GWAS meta‐analyses were not confounded by underlying population stratification.

**Figure S4.** Results of GWAS meta‐analysis for circulating glycine levels in men. A, The Manhattan plot shows 9 loci significantly associated with circulating glycine levels in a stratified GWAS analysis with 19 004 men. The 5 loci identified in previous studies are indicated by blue dots. The red dots indicate association signals at the 7 novel identified by our meta‐analysis with all 30 118 subjects, of which 4 were also significant in only men. Genome‐wide thresholds for significant (*P*=5.0×10^−8^) and suggestive (*P*=5.0×10^−6^) association are indicated by the horizontal red and dark blue lines, respectively. *P* values are truncated at −log10 (*P*)=40. B, The Q‐Q plot shows the observed vs the expected *P* values from the meta‐analyses for glycine levels in men. These analyses yielded a genomic inflation factor (λ) of 1.035, indicating that the GWAS meta‐analyses were not confounded by underlying population stratification.

**Figure S5.** Sex‐stratified results for 12 loci identified for circulating glycine levels. Effect sizes for the lead SNPs at the 12 loci identified for circulating glycine levels are shown in men (blue) and women (red) separately. With the exception of *CPS1*, which is associated with ≈2‐fold higher glycine levels in women compared with men, effect sizes at the 11 other loci were similar in males and females. EA indicates effect allele; OA, other allele.
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**Table S1.** Results of 12 Loci Significantly Associated With Circulating Glycine Levels Stratified by Metabolomics Platform

**Table S2.** Results of 12 Loci Significantly Associated With Circulating Glycine Levels Stratified by Sex

**Table S3.** PheWAS Results for 12 Loci Significantly Associated With Circulating Glycine Levels

**Table S4.** Association of 12 Glycine‐Associated Loci With CAD in CARDIoGRAM+C4D and UK Biobank

**Table S5.** Individual and Joint SNP Effect Associations and Mendelian randomization analysis of Glycine‐Associated Loci With Traditionally CAD Risk Factors
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